Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers

Lynn M Malec, MD, Stacy E. Croteau, Michael Callaghan, MD, Davide Matino, MD MSc, Kenneth Dale Friedman, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 2407.

https://doi.org/10.1182/blood-2019-126196

Published: 2019

Journal Articles

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Louis M. Aledort, MD, Nisha Jain, MBBS,MD, Nanxin Li, Sangeeta Krishnan, PharmD, Benjamin Hagberg, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2018-99-114905

Published: 2018

Journal Articles

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children < 12 Years of Age with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Gili Kenet, MD, Andres Brainsky, MD, Jerry S. Powell, MD, Yanyan Li, PhD, Wilfried Seifert, PhD

Blood (2017) 130 (Supplement 1): 2370.

https://doi.org/10.1182/blood.V130.Suppl_1.2370.2370

Published: 2017

Journal Articles

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Adolescents/Adults with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Ingrid Pabinger, MD, Elena Santagostino, Andres Brainsky, MD, Jerry S. Powell, MD, Yanyan Li, PhD, Wilfried Seifert, PhD

Blood (2017) 130 (Supplement 1): 3690.

https://doi.org/10.1182/blood.V130.Suppl_1.3690.3690

Published: 2017

Journal Articles

Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

John Roberts, PhD, Cecilia Fosser, PhD, Michael Tortorici, PhD PharmD, Alex Veldman, MD, Iris C. Jacobs, MD, Jagdev Sidhu, PhD

Blood (2016) 128 (22): 1411.

https://doi.org/10.1182/blood.V128.22.1411.1411

Published: 2016

Journal Articles

Pharmacokinetics of Idelvion (rIX-FP) in a Patient with Renal Failure

Adam S. Kotowski, MD, Shilpa Jain, MD MPH, Steven John Ambrusko, MD MS, Linda Belling, RN, Karen Kovach, MT, ASCP, SH

Blood (2016) 128 (22): 4957.

https://doi.org/10.1182/blood.V128.22.4957.4957

Published: 2016

Journal Articles

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Elena Santagostino, Uri Martinowitz, Toshko Lissitchkov, Brigitte Pan-Petesch, Hideji Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Negrier, Ingrid Pabinger, Mario von Depka Prondzinski, Carmen Altisent, Giancarlo Castaman, Koji Yamamoto, Maria-Teresa Álvarez-Roman, Christine Voigt, Nicole Blackman, Iris Jacobs

Blood (2016) 127 (14): 1761–1769.

https://doi.org/10.1182/blood-2015-09-669234

Published: 2016

Includes: Supplemental data

Journal Articles

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Elena Santagostino, MD PhD, Christine Voigt, PhD, Denise Wolko, Grace Cole, Yanyan Li, PhD, Iris C. Jacobs, MD

Blood (2015) 126 (23): 548.

https://doi.org/10.1182/blood.V126.23.548.548

Published: 2015

Journal Articles

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Aaron Lubetsky, MD, Uri Martinowitz, MD, Toshko Lissitchkov, MD, Christine Voigt, PhD, Denise Wolko, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 1096.

https://doi.org/10.1182/blood.V126.23.1096.1096

Published: 2015

Journal Articles

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Claude Negrier, MD, Lynda Mae Lepatan, MD, Faralzah Karim, MD, Anne Lienhart, MD, Denise Wolko, Christine Voigt, PhD, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2298.

https://doi.org/10.1182/blood.V126.23.2298.2298

Published: 2015

Journal Articles

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Elena Santagostino, MD PhD, Iris C. Jacobs, MD, Christine Voigt, PhD, Annettee Feussner, PhD, Tharin Limsakun, PhD

Blood (2014) 124 (21): 1491.

https://doi.org/10.1182/blood.V124.21.1491.1491

Published: 2014

Journal Articles

Prolonging the Half-Life of Hemostatic Factors via the Neonatal Fc Receptor

Robert Peters, Ph.D.

Blood (2013) 122 (21): SCI-8.

https://doi.org/10.1182/blood.V122.21.SCI-8.SCI-8

Published: 2013

Journal Articles

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Aaron Lubetsky, MD MSc, Toshko Lissitchkov, MD, Elena Santagostino, MD, PhD, Gantcho Jotov, MD, Tami Barazani-Brutman, Ph.D, Christine Voigt, Ph.D, Tina Moises, Ph.D, Iris C. Jacobs, MD, Uri Martinowitz, MD

Blood (2013) 122 (21): 1109.

https://doi.org/10.1182/blood.V122.21.1109.1109

Published: 2013

Journal Articles

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

Uriel Martinowitz, MD, Aaron Lubetsky, MD, Elena Santagostino, MD, PhD, Gantcho Jotov, MD, Jacob Luboshitz, MD, Shadan Lalezari, MD, Tami Barazani-Brutman, Ph.D, Christine Voigt, Ph.D, Tina Moises, Ph.D, Iris C. Jacobs, MD, Toshko Lissitchkov

Blood (2012) 120 (21): 1121.

https://doi.org/10.1182/blood.V120.21.1121.1121

Published: 2012

Journal Articles

Biodistribution of the Recombinant Fusion Protein Linking the Human Factor IX to Human Albumin (rIX-FP) in Rats

Eva Herzog, Stephen Harris, Andrew McEwen, Ingo Pragst, Gerhard Dickneite, Stefan Schulte, PhD, Sabine Zollner

Blood (2012) 120 (21): 1117.

https://doi.org/10.1182/blood.V120.21.1117.1117

Published: 2012

Journal Articles

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Elena Santagostino, Claude Negrier, Robert Klamroth, Andreas Tiede, Ingrid Pabinger-Fasching, Christine Voigt, Iris Jacobs, Massimo Morfini

Blood (2012) 120 (12): 2405–2411.

https://doi.org/10.1182/blood-2012-05-429688

Published: 2012

NARROW

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children < 12 Years of Age with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Adolescents/Adults with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

Pharmacokinetics of Idelvion (rIX-FP) in a Patient with Renal Failure

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Prolonging the Half-Life of Hemostatic Factors via the Neonatal Fc Receptor

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

Biodistribution of the Recombinant Fusion Protein Linking the Human Factor IX to Human Albumin (rIX-FP) in Rats

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only